Filing Details

Accession Number:
0001104659-25-006733
Form Type:
13D Filing
Publication Date:
2025-01-27 19:00:00
Filed By:
Denise Carter
Company:
Quoin Pharmaceuticals Ltd.
Filing Date:
2025-01-28
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Denise Carter 939,238 0 939,238 0 939,238 4.9%
Filing





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
(1) Reported securities are represented by American Depositary Shares (ADSs). Each ADS represents one Ordinary Share of the Issuer. Rows 7, 9 and 11 include (i) 602,648 ADSs held directly, (ii) 19,765 ADSs issuable within 60 days of the filing of this statement on Schedule 13D (this "Statement") upon the exercise of outstanding options and (iii) 316,826 ADSs issuable upon the exercise of outstanding warrants. Excludes (i) 604,953 ADS issuable upon the exercise of outstanding options which are not exercisable within 60 days of this Statement, and (ii) 794,286 shares issuable pursuant to warrants which are not currently exercisable due to a 4.99 percent ownership blocker. (2) Percentage calculated based on 18,485,830 Ordinary Shares outstanding as of January 27, 2025. This Amendment No. 1 to Schedule 13D amends and supplements the previously filed Schedule 13D filed by Denise Carter (the "Reporting Person"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.


SCHEDULE 13D

 
Denise Carter
 
Signature:/s/ Denise Carter
Name/Title:Denise Carter
Date:01/28/2025